Professional Documents
Culture Documents
Ostermann Bob Hollar
Ostermann Bob Hollar
Ostermann Bob Hollar
Hello!
Dr. Ostermann:
Bob Hollar:
Am I pronouncing your
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Sure.
Bob Hollar:
If you will, I will ask you a moment. I will explain that first
of all introduce myself. I am Bob Hollar and I am with the
company Giles & Associates and we are a consulting firm
so working with the client currently in the healthcare
industry who is investigating a vaccine for CMV and...
Dr. Ostermann:
Very good.
Bob Hollar:
Dr. Ostermann:
Sure.
Bob Hollar:
Sounds good.
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Okay.
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Yes, yes.
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
It is lower.
Bob Hollar:
Okay.
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Okay.
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Okay, and how would you compare their risk to like the
baseline dialysis patients? Are the posttreatment lupus
patients greater or equivalent risk or low?
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Okay.
Dr. Ostermann:
Bob Hollar:
I see.
Dr. Ostermann:
Bob Hollar:
Okay, and then tell me a little bit about the patients that
you might be treating with that might be enhanced their
elevated CMV risk because of their immunosuppression
from a cancer treatment. I assume that the once that you
see would have either some you would be consulting on
the basis of the renal aspect. Would their disease have to
involve their kidney or would you just be involved in a lot
of those cases just to kind of consult with regards to
kidney function? Explained how work the patient.
Dr. Ostermann:
Bob Hollar:
I see.
Dr. Ostermann:
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Okay.
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Sure.
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Okay.
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Okay.
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Thats right.
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Okay.
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
It
is
the
burden
or
this
intensity
immunosuppression right in the beginning.
Bob Hollar:
Dr. Ostermann:
Yes, correct.
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Okay.
Dr. Ostermann:
Bob Hollar:
Okay.
Dr. Ostermann:
Bob Hollar:
So, I am sorry did I hear that you even monitor the minusminus patients?
Dr. Ostermann:
Bob Hollar:
And you could you break down how often you might
expect to see? Do you see any significant incidence of
disease in any of those groups?
Dr. Ostermann:
of
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Okay.
Now tell me more in the case of
immunosuppressed cancer. This is typically patients
have received such extent the chemotherapy
radiation therapy in that their immune systems
depleted is that right?
Dr. Ostermann:
Thats right.
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
the
who
and
are
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
How do we monitor?
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Okay, and when these symptoms did show up, would that
be the next step as to do a blood test?
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
PCR, yes.
Bob Hollar:
Okay, and what would you look for in that test result to
base your decision upon further action? What kind of PCR
result would trigger a response?
Dr. Ostermann:
Is that the
Okay.
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Okay.
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Okay.
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Correct.
Bob Hollar:
Dr. Ostermann:
ventilator
may
have
immunosuppression.
been
associated
with
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
I see.
Dr. Ostermann:
Bob Hollar:
Is it possible that you can sort of, are there any trends
with regards to when you might see CMV incidence in
terms of when during their stay in the ICU so you see
some infections or disease immediately or does it
basically just increase gradually over time?
[PHONE RINGING]
Dr. Ostermann:
Bob Hollar:
Sure.
[ANSWERING PHONE]
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Okay.
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Okay.
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Okay.
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Okay.
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Yes.
Dr. Ostermann:
Dr. Ostermann:
Bob Hollar:
Okay.
Once they become infected and have been
diagnosed, do you then monitor their CMV load
subsequently during treatment? How is that?
Dr. Ostermann:
Yeah.
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Okay.
Dr. Ostermann:
Bob Hollar:
Okay.
Dr. Ostermann:
Bob Hollar:
Okay. Let me just get down here. So, you typically would
not be aware necessarily of any subclinical infection of
CMV that might be sort of testing prior to producing any
sort of clinical symptoms, right so..?
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
I see.
Dr. Ostermann:
Bob Hollar:
I see.
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
To valaciclovir?
Dr. Ostermann:
Sorry, valganciclovir.
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Okay.
Dr. Ostermann:
Bob Hollar:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Okay, sure.
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Okay.
Dr. Ostermann:
Bob Hollar:
Bob Hollar:
Correctly?
Dr. Ostermann:
Correct.
Bob Hollar:
So, doctor did you receive the discussion guide and the
materials that were sent in advance by email by any
chance?
Dr. Ostermann:
Yes, I did.
Bob Hollar:
[PAUSE]
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
5.
Bob Hollar:
Okay. How does that [clears throat] pardon me, the 40%
reduction in CMV disease or viremia, how does that stick
with your expertise? Okay?
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Bob Hollar:
Dr. Ostermann:
Sure.
Bob Hollar:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Unless
Bob Hollar:
Okay.
Is there anything that would prevent you or
dissuade you from using a vaccine like this? What would
be the things that you would need to satisfy yourself of
prior to use?
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Dr. Ostermann:
No not really,
questions.
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
Dr. Ostermann:
Bob Hollar:
think
you
have
asked
those
Bob Hollar:
Dr. Ostermann:
T: BCM
D: 03/16/13